Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$11.83 - $24.05 $123,777 - $251,635
10,463 New
10,463 $179,000
Q2 2023

Aug 10, 2023

BUY
$40.29 - $82.51 $34,891 - $71,453
866 Added 11.49%
8,401 $349,000
Q1 2023

May 11, 2023

SELL
$56.44 - $118.81 $11,852 - $24,950
-210 Reduced 2.71%
7,535 $453,000
Q4 2022

Feb 07, 2023

BUY
$63.98 - $85.37 $51,120 - $68,210
799 Added 11.5%
7,745 $568,000
Q3 2022

Nov 14, 2022

SELL
$67.99 - $89.57 $49,496 - $65,206
-728 Reduced 9.49%
6,946 $527,000
Q2 2022

Jul 19, 2022

SELL
$56.6 - $89.9 $37,582 - $59,693
-664 Reduced 7.96%
7,674 $533,000
Q1 2022

May 04, 2022

SELL
$60.15 - $84.52 $13,774 - $19,355
-229 Reduced 2.67%
8,338 $690,000
Q4 2021

Jan 31, 2022

BUY
$75.08 - $121.99 $224,113 - $364,140
2,985 Added 53.48%
8,567 $643,000
Q3 2021

Oct 29, 2021

SELL
$116.17 - $194.55 $18,471 - $30,933
-159 Reduced 2.77%
5,582 $648,000
Q2 2021

Aug 11, 2021

BUY
$130.4 - $225.58 $47,204 - $81,659
362 Added 6.73%
5,741 $1.27 Million
Q1 2021

May 04, 2021

SELL
$124.11 - $190.17 $263,237 - $403,350
-2,121 Reduced 28.28%
5,379 $711,000
Q4 2020

Feb 11, 2021

BUY
$112.16 - $174.14 $30,171 - $46,843
269 Added 3.72%
7,500 $1.3 Million
Q3 2020

Nov 05, 2020

SELL
$58.05 - $111.31 $3,134 - $6,010
-54 Reduced 0.74%
7,231 $804,000
Q2 2020

Aug 12, 2020

BUY
$57.2 - $74.41 $151,236 - $196,740
2,644 Added 56.97%
7,285 $432,000
Q1 2020

May 11, 2020

SELL
$57.05 - $95.75 $16,829 - $28,246
-295 Reduced 5.98%
4,641 $312,000
Q4 2019

Feb 05, 2020

BUY
$68.3 - $93.8 $114,334 - $157,021
1,674 Added 51.32%
4,936 $415,000
Q3 2019

Oct 30, 2019

BUY
$61.86 - $97.8 $201,787 - $319,023
3,262 New
3,262 $243,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.79B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.